Lenus Health GmbH

Lenus Health GmbH Overview

Lenus Health GmbH is a registered pharmaceutical broker in accordance with Section 52b AMG based in Haiterbach, Baden-Württemberg. The company brokers transactions for human medicines without physically handling the goods.

Tätigkeitsfeld & Registrierung

Lenus Health GmbH is registered with the responsible state authority in accordance with Section 52b AMG and is subject to the requirements of Good Sales Practice (GDP). The company mediates transactions between manufacturers, wholesalers and buyers.

About Lenus Health GmbH

Innovative healthcare solutions with a global vision

Location & Contact

Lenus Health GmbH can be reached at the following address: Hermann-Hesse-Str. 17, 72221 Haiterbach – Phone: 030767598844. For current information and enquiries, please contact the company directly.

More information: Arzneimittelvermittler in Baden-Württemberg or all Arzneimittelvermittler in Germany on Sanoliste.

Arzneimittelvermittlung nach § 52b AMG

Drug brokers such as Lenus Health GmbH mediate the purchase and sale of human drugs without physically acquiring possession of the goods themselves. The activity is regulated in Germany according to Section 52b of the Medicines Act (AMG). Intermediaries must be registered with the relevant state authority and ensure compliance with Good Sales Practices (GDP).

Regulatorische Anforderungen

Lenus Health GmbH is subject to strict requirements: registration with the BfArM, compliance with GDP guidelines, documented qualification of business partners (manufacturers, wholesalers, pharmacies) and complete traceability of all mediated transactions. Unlike wholesalers, intermediaries do not need a wholesale license, but they must maintain a quality assurance system and carry out self-inspections.

Marktrolle & Bedeutung

Drug intermediaries play an important role in the European pharmaceutical market, particularly in cross-border trade. Lenus Health GmbH in Haiterbach acts as an interface between manufacturers and buyers and enables efficient pharmaceutical trading. Intermediary activity is becoming increasingly important as global supply chains become more complex.